Multiplicom CLL MASTR Plus
Multiplicom has announced the commercial release of a new gene sequencing panel, the CLL MASTR Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. CLL MASTR Plus detects single nucleotide variants and copy number alterations in nine genes that are frequently mutated in CLL, and is intended to provide information to guide treatment options. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation, Multiplicom noted. MASTR kits are compatible with leading NGS platforms, the company added.